Crosslinked nucleoside intermediate crystal and method for producing the same, and method for producing crosslinked nucleoside amidite

A crystalline form of cross-linked nucleoside intermediates addresses the instability issue in existing methods, enabling stable storage and efficient conversion into cross-linked nucleoside amidites for industrial use.

JP2024169733APending Publication Date: 2024-12-05YAMASA SHOYU CO LTD
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
JP2024169337
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2019-06-19
Filing Date
2024-09-27
Publication Date
2024-12-05

AI Technical Summary

Technical Problem

Existing methods for synthesizing cross-linked nucleosides require unstable reaction intermediates, making it difficult to store and use them effectively for industrial production.

Method used

The development of a crystalline form of cross-linked nucleoside intermediates, characterized by specific substituents, which can be stably stored and used to produce cross-linked nucleoside amidites through a series of chemical transformations.

Benefits of technology

The crystalline form of cross-linked nucleoside intermediates can be stored stably for a long period and efficiently converted into cross-linked nucleoside amidites, reducing the need for complex purification steps and enhancing industrial applicability.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024169733000001_ABST
    Figure 2024169733000001_ABST
Patent Text Reader

Abstract

To provide a crystal of a compound that can be stably stored for a long time and can be used as a crosslinked nucleoside intermediate.SOLUTION: The invention relates to a crystal of a compound represented by the formula 5 in the figure, where R1 represents a protecting group for a hydroxyl group, and R2 represents a leaving group.SELECTED DRAWING: Figure 1
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present disclosure relates to crystals of bridged nucleoside intermediates and methods for producing the same, as well as methods for producing bridged nucleoside amidites. [Background technology]

[0002] Methods for treating diseases using nucleic acid medicines include the antisense method, antigene method, aptamer method, and siRNA method.

[0003] The furanose ring of the nucleoside sugar moiety is usually not planar but has distorted conformations called N- or S-type, and certain conformations are biased by the substituents on the ring. For example, in the case of ribonucleosides that have a hydroxyl group at the 2'-position, the N-type conformation is dominant. Imanishi et al. succeeded in forcibly fixing the conformation of nucleosides to N-type by bridging the 4' and 2' hydroxyl groups of the nucleoside sugar moiety. As a result, it was revealed that LNAs (Locked Nucleic Acids) containing this bridged nucleoside form extremely stable double strands with nucleic acids of complementary sequences (see Patent Document 1). Due to the above-mentioned characteristics, expectations for LNA as a material for nucleic acid drugs have been growing in recent years.

[0004] Known examples of methods for synthesizing bridged nucleosides include a method using a nucleoside as a starting material (Patent Document 1) and a method using a sugar as a starting material (Patent Document 2, Non-Patent Document 1, Non-Patent Document 2).

[0005] Among the existing methods for synthesizing bridged nucleosides, the following synthesis method has been proposed by Tohoku University as one of the most excellent methods (Non-Patent Document 3).

[0006] [ka] [Prior art documents] [Patent documents]

[0007] [Patent Document 1] Japanese Patent Application Publication No. 10-304889 [Patent Document 2] Special Publication No. 2002-521310 [Non-patent literature]

[0008] [Non-Patent Document 1] J. Org. Chem. 2001, 66, 8504-8512 [Non-Patent Document 2] Tetrahedron 1998,54,3607-3630 [Non-Patent Document 3] Doctoral thesis, Tohoku University (11301-17068, 2016) Summary of the Invention [Problem to be solved by the invention]

[0009] Existing methods for synthesizing bridged nucleosides (for example, the methods described in Patent Documents 1 and 2 and Non-Patent Document 2) aim to synthesize bridged nucleoside amidites through a series of steps. Therefore, at present, the stability and storage of the reaction intermediates (hereinafter sometimes referred to as "bridged nucleoside intermediates") have not been considered.

[0010] However, the inventors have found that the existing methods for synthesizing bridged nucleosides have a problem in that they require the intermediate to be relatively unstable. When industrially producing bridged nucleosides, it is necessary to synthesize a plurality of bridged nucleosides from a specific intermediate as necessary, and ideally, it is desirable to be able to store the specific intermediate stably. That is, an object of the present disclosure is to provide a crystal of a compound that can be used as a bridged nucleoside intermediate that can be stably stored for a long period of time, and a method for producing the same. Another object of the present disclosure is to provide a method for producing a bridged nucleoside amidite using the crystal of the compound. [Means for solving the problem]

[0011] As a result of investigations conducted by the inventors to solve the above problems, they discovered that a compound having a specific substituent can be easily crystallized and can be stably stored in the crystalline form as a bridged nucleoside intermediate.

[0012] That is, the present disclosure relates to the inventions identified below. [1] A crystal of the compound represented by the following formula 5.

[0013] [ka]

[0014] In the above formula, R 1 is a protecting group for the hydroxyl group, R 2 indicates a leaving group.

[0015] [2] The crystal described in [1] shows peaks at diffraction angles (2θ) of 5.9±0.3, 11.4±0.6, 11.8±0.6, 13.2±0.7, 16.2±0.8, 17.2±0.9, 18.5±0.9, 19.5±1.0, 19.7±1.0, 20.1±1.0, 20.4±1.0, 21.4±1.1, 22.0±1.1, 23.0±1.2, 24.1±1.2, 24.3±1.2, 26.4±1.3, and 29.9±1.5 (°) in powder X-ray analysis.

[0016] [3] The crystal according to [1] or [2], which shows an endothermic peak at 124°C when measured by a thermogravimetry / differential thermal analysis (TG / DTA) apparatus.

[0017] [4] The crystal according to any one of [1] to [3], wherein the compound represented by formula 5 is a bridged nucleoside intermediate.

[0018] [5] A method for producing a crystal of a compound represented by formula 5, comprising the following steps 1 to 5: Step 1: protecting the hydroxyl group of a compound represented by formula 1 to obtain a compound represented by formula 2; Step 2: converting the dimethyldioxolanyl group at the 4-position of the compound represented by formula 2 into an aldehyde group to obtain a compound represented by formula 3; Step 3: reducing the compound represented by formula 3 to convert the aldehyde group at the 4-position into a hydroxyl group to obtain a compound represented by formula 4; Step 4: converting the 4-hydroxyl group of the compound represented by formula 4 into a leaving group to obtain a compound represented by formula 5; Step 5: crystallizing the compound represented by formula 5 from a crystallization solvent to obtain crystals of the compound represented by formula 5

[0019] [ka]

[0020] In the above formula, R 1 is a protecting group for the hydroxyl group, R 2 indicates a leaving group.

[0021] [6] A method for producing the crystal described in [5], further comprising a crystallization step between steps 2 and 3.

[0022] [7] The method for producing the crystal according to [5] or [6], wherein the compound represented by formula 5 is a bridged nucleoside intermediate.

[0023] [8] A method for producing a bridged nucleoside amidite, comprising the steps of: Step 6: A step of suspending crystals of the compound represented by formula 5 obtained by any one of the production methods [5] to [7] in a solvent, and then converting the isopropylidene group of the compound to an acetyl group to obtain the compound represented by formula 6. Step 7: Condensing the compound represented by formula 6 with a silylated base to obtain the compound represented by formula 7 Step 8: A step of removing the protecting group of the compound represented by formula 7 and simultaneously carrying out a cyclization reaction to obtain a compound represented by formula 8. Step 9: Removing the hydroxyl-protecting group of the compound represented by formula 8 to obtain a compound represented by formula 9 Step 10: A step of introducing a protecting group into the amino group of the base moiety of the compound represented by formula 9, if necessary, to obtain a compound represented by formula 10.

[0024] [ka] In the above formula, R 1 is a protecting group for the hydroxyl group, R 2 is a leaving group, R 3 represents a hydrogen atom or an amino-protecting group. Effect of the Invention

[0025] According to the present disclosure, it is possible to provide a crystal of a compound that can be used as a bridged nucleoside intermediate that can be stably stored for a long period of time, and a method for producing the same. In addition, according to the present disclosure, it is possible to provide a method for producing a bridged nucleoside amidite using the crystal of the compound. [Brief description of the drawings]

[0026] [Figure 1] FIG. 1 shows a photograph of the crystals of the compound represented by formula 5. [Diagram 2] FIG. 2 shows a powder X-ray diffraction spectrum of the crystal of the compound represented by formula 5. [Diagram 3] FIG. 3 shows the results of thermogravimetry / differential thermal analysis of the crystals of the compound represented by formula 5. [Figure 4] FIG. 4 shows the results of an accelerated test of the crystals of the compound represented by formula 5. [Diagram 5]Fig. 5(a) shows the results of TLC analysis of the solution of the crystals of the compound represented by formula 3 obtained in step 2. Fig. 5(b) shows the results of TLC analysis of the reaction solution of the compound represented by formula c obtained under the conditions described in Non-Patent Document 3. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0027] Hereinafter, the embodiments of the present disclosure will be described in detail with reference to the drawings. The present disclosure is not limited to the following embodiments, and it should be understood that modifications and improvements to the following embodiments based on the ordinary knowledge of a person skilled in the art are also included in the scope of the present disclosure, without departing from the spirit of the present disclosure.

[0028] As described above, the present disclosure relates to a crystal of a compound represented by the following formula 5.

[0029] [ka]

[0030] In the above formula, R 1 is a protecting group for the hydroxyl group, R 2 indicates a leaving group.

[0031] The crystals of the present disclosure exhibit an appearance as shown in FIG. 1 when observed under a microscope as described in the Examples below.

[0032] The crystals of the present disclosure have characteristic peaks in powder X-ray analysis. In this specification, the powder X-ray diffraction is performed under the following conditions. [X-ray analysis equipment] X'Pert PRO MPD (Spectris) [Target] Cu [X-ray tube current] 40mA [X-ray tube voltage] 45kV [Scan range] 2θ=4.0~40°

[0033] When the crystals of the present disclosure are analyzed using a powder X-ray diffractometer under the conditions described above, they show characteristic peaks near the diffraction angles (2θ) shown in Table 1 below (see FIG. 2), as described in the Examples below.

[0034] [Table 1]

[0035] When the crystals of the present disclosure are analyzed by a powder X-ray diffractometer under the above conditions, peaks with relative intensities of 10% or more are shown at 5.9, 11.4, 11.8, 13.2, 16.2, 17.2, 18.5, 19.5, 19.7, 20.1, 20.4, 21.4, 22.0, 23.0, 24.1, 24.3, 26.4, and 29.9 (°).

[0036] Generally, the diffraction angle (2θ) in powder X-ray diffraction may include an error range of less than 5%. Therefore, in addition to crystals in which the diffraction angles of peaks in powder X-ray diffraction are completely the same, crystals in which the diffraction angles of peaks match with an error of less than 5% are also included in the crystals of the present disclosure. In powder X-ray diffraction, for example, the diffraction angles (2θ) of peaks with relative intensities of 10% or more are 5.9±0.3, 11.4±0.6, 11.8±0.6, 13.2±0.7, 16.2±0.8, 17.2±0.9, 18.5±0.9, 19.5±1.0, 19.7±1.0, 20.1±1.0, 20.4±1.0, 21.4±1.1, 22.0±1.1, 23.0±1.2, 24.1±1.2, 24.3±1.2, 26.4±1.3, and 29.9±1.5 (°).

[0037] As described in the Examples below, the crystals of the compound represented by formula 5 of the present disclosure have an endothermic peak at 124° C. when analyzed by a thermogravimetry / differential thermal analysis (TG / DTA) apparatus (heating rate 5° C. / min) (see FIG. 3 ).

[0038] In this specification, thermogravimetry / differential thermal analysis (TG / DTA) is performed under the following conditions. [Equipment used] Thermal analysis equipment STA7200 (Hitachi High-Tech Science) [Measurement conditions] The temperature is raised by 5°C per minute in the range of 30 to 190°C, and the change in heat of the sample is measured. Aluminum oxide is used as a reference.

[0039] The crystals of the compound represented by formula 5 of the present disclosure can be stably stored at room temperature for a long period of time. The long-term stability of the compound can be evaluated by carrying out an accelerated test under the conditions described in the Examples below. In this case, the crystals of the present disclosure exhibit an HPLC purity of 90% or more, preferably 95% or more, more preferably 98% or more, even more preferably 99% or more, and even more preferably 99.5% or more, even after the accelerated test (see FIG. 4).

[0040] The present disclosure also relates to a method for producing a crystal of a compound represented by formula 5, comprising the following steps 1 to 5: Step 1: protecting the hydroxyl group of a compound represented by formula 1 to obtain a compound represented by formula 2; Step 2: converting the dimethyldioxolanyl group at the 4-position of the compound represented by formula 2 into an aldehyde group to obtain a compound represented by formula 3; Step 3: reducing the compound represented by formula 3 to convert the aldehyde group at the 4-position into a hydroxyl group to obtain a compound represented by formula 4; Step 4: converting the 4-hydroxyl group of the compound represented by formula 4 into a leaving group to obtain a compound represented by formula 5; Step 5: crystallizing the compound represented by formula 5 from a crystallization solvent to obtain crystals of the compound represented by formula 5

[0041] [ka] In the above formula, R 1 is a protecting group for the hydroxyl group, R 2 indicates a leaving group.

[0042] The synthesis method using the compound represented by formula 1 as a starting material and including steps 1 to 5 will be described in detail below.

[0043] The compound represented by formula 2 can be obtained by protecting the hydroxyl groups at the 3-position and 5-position of the compound represented by formula 1 with a 4-substituted benzyl group. Among the 4-substituted benzyl groups, 4-halobenzyl groups such as 4-fluorobenzyl group, 4-chlorobenzyl group, 4-bromobenzyl group, and 4-iodobenzyl group, and 4-nitrobenzyl group are preferred because the compound represented by formula 5 of the present disclosure exhibits good crystallinity. Among these, 4-chlorobenzyl group, 4-bromobenzyl group, 4-iodobenzyl group, and 4-nitrobenzyl group are preferred because the compound represented by formula 5 of the present disclosure exhibits high crystallinity, and 4-bromobenzyl group is preferred in terms of availability and cost.

[0044] The introduction of a 4-substituted benzyl group into the compound represented by formula 1 may be carried out according to a known method. For example, in the case of introducing a 4-bromobenzyl group, the compound may be treated with NaH in DMF at 0°C for about 15 minutes to 3 hours, and then reacted with 4-bromobenzyl bromide at room temperature for 1 hour to 24 hours. Schotten-Baumann type conditions may also be used by combining an aqueous sodium hydroxide solution, an aqueous potassium hydroxide solution, and an organic solvent such as a halogen-based solvent such as dichloromethane or chloroform, or an ether-based solvent such as tetrahydrofuran or 2-methyltetrahydrofuran. Furthermore, various methods for introducing a protecting group described in Protective Groups in ORGANIC SYNTHESIS may also be used.

[0045] The compound represented by formula 1 is known, and commercially available compounds can be used, or the compound can be synthesized by a known method (for example, J. Org. Chem. 2015, 80, 5337-5343).

[0046] Step 2 is a step of converting the dimethyldioxolanyl group at the 4-position of the compound represented by formula 2 into an aldehyde group to obtain a compound represented by formula 3.

[0047] In this step, a deprotecting agent is added to deprotect the dimethyldioxolanyl group at the 4-position to form a diol. The deprotecting agent may be acetic acid, trifluoroacetic acid, hydrochloric acid, sulfuric acid, iodine, or the like. Among these, acetic acid is preferably used because of its availability and ease of handling. The amount of the deprotecting agent to be added can be appropriately set depending on the type of the deprotecting agent, but in the case of acetic acid, for example, it is preferable to use the amount of the solvent. In addition, as described later, water is preferably used as an auxiliary solvent because purification by crystallization is easy. The ratio of the deprotecting agent to the auxiliary solvent is preferably about 10:1 to 1:1 on a volume basis, and more preferably 2:1.

[0048] In this step, an oxidizing agent is used to oxidatively cleave the diol resulting from deprotection of the dimethyldioxolanyl group at the 4-position and convert it to an aldehyde group. Usable oxidizing agents include periodates such as sodium periodate and potassium periodate, and lead tetraacetate. Among these, it is preferable to use 1 to 10 molar equivalents of sodium periodate relative to the diol from the standpoint of cost, toxicity, etc. Furthermore, the amount used is more preferably 1 to 2 molar equivalents.

[0049] In step 2, an additive may be used to increase the reactivity of the oxidizing agent. An example of the additive is iodine.

[0050] Among the combinations of reaction conditions for the above step 2, it is preferable to use acetic acid as the deprotecting agent, water as the solvent, and sodium periodate as the oxidizing agent. When these conditions are used, the reaction can be carried out at 0 to 100° C. The reaction temperature is more preferably about 50 to 80° C. Under the above conditions, the reaction can be carried out for 1 to 24 hours. The use of this combination is suitable for industrial production, since there is no excess iodine in the reaction system, and the solvent after the reaction is easily disposed of. In addition, the use of the compound represented by formula 1 allows the target compound represented by formula 3 to be obtained in a high yield of 70 to 90% or more by crystallization without using a purification means such as chromatography.

[0051] Step 3 is a step of reducing the compound represented by formula 3 to convert the aldehyde group at the 4-position into a hydroxyl group, thereby obtaining a compound represented by formula 4.

[0052] In this step, it is necessary to add a reducing agent. The type of reducing agent is not particularly limited, but for example, sodium borohydride, lithium aluminum hydride, borane derivatives, catalytic reduction, etc. can be used. Among these, it is preferable to use sodium borohydride from the viewpoint of cost and safety. The amount of the reducing agent to be added can be appropriately adjusted depending on the type of reducing agent. For example, in the case of sodium borohydride, it is preferable to use 0.25 to 10 molar equivalents, more preferably 0.25 to 2 molar equivalents, relative to the compound represented by formula 3. Under the above conditions, the reaction can be carried out at -30 to 50°C, more preferably -10 to 25°C, for 10 to 120 minutes.

[0053] The solvent in this step can be appropriately used depending on the type of reducing agent, etc. For example, water can be used as the aqueous solvent, and alcohol solvents such as methanol and ethanol, tetrahydrofuran, 2-methyltetrahydrofuran, 4-methyltetrahydropyran, and combinations of these with water can be used as the organic solvent.

[0054] Step 4 is a step of converting the hydroxyl group at position 4 of the compound represented by formula 4 to a leaving group to obtain a compound represented by formula 5.

[0055] The leaving group introduced in this step is not particularly limited, but in order to efficiently carry out the crosslinking reaction, it is preferable that the leaving group is a substituent with high reactivity in the nucleophilic substitution reaction. Examples of such a substituent include 4-toluenesulfonyloxy group, methanesulfonyloxy group, chloromethanesulfonyloxy group, trifluoromethanesulfonyloxy group, halogeno group, etc. Among these, the 4-toluenesulfonyloxy group is preferred because the leaving group introduction reagent is easily available and inexpensive.

[0056] The solvent used in this step can be appropriately selected from organic solvents or combinations of water and organic solvents depending on the type of leaving group to be introduced. Specifically, the organic solvent can be a combination of a halogenated solvent such as pyridine, dichloromethane, or chloroform with an organic base such as triethylamine, or the aqueous solvent can be a combination of an organic base such as water-triethylamine, an aqueous sodium hydroxide solution, or an aqueous potassium hydroxide solution with an organic solvent such as a halogenated solvent such as dichloromethane or chloroform, or an ether solvent such as tetrahydrofuran or 2-methyltetrahydrofuran, under Schotten-Baumann type conditions. Among these, it is preferable to use any of pyridine, an aqueous sodium hydroxide solution-tetrahydrofuran, or an aqueous sodium hydroxide solution-2-methyltetrahydrofuran in terms of toxicity and cost. The amount of the reagent for introducing the leaving group can be appropriately selected depending on the type of the substituted leaving group and the solvent. For example, when 4-toluenesulfonyl chloride is used as the leaving group and pyridine is used as the solvent, it is preferable to use 1 to 10 molar equivalents relative to the compound represented by formula 3, and more preferably 1 to 2 molar equivalents. The reaction may be carried out under the above conditions at a temperature of -10 to 100°C, more preferably at 0 to 60°C, for 1 to 24 hours.

[0057] Step 5 is a step of performing a post-treatment operation on the synthesis reaction solution of the compound represented by formula 5 to obtain crystals of the compound represented by formula 5. Examples of the crystallization solvent for the compound represented by formula 5 include alcohol solvents such as ethanol and combinations of various good solvents and poor solvents. Examples of the good solvent include ethyl acetate, tetrahydrofuran, pyridine, chloroform, acetonitrile, acetone, and derivatives thereof. Examples of the poor solvent include hexane, alcohol, water, and derivatives thereof.

[0058] In each of the above steps, if necessary, an isolation / purification operation may be performed after the completion of the step, but it is not necessary to perform such an operation. Examples of isolation / purification methods include various types of chromatography such as ion exchange and adsorption, and crystallization. Since the compound obtained by the synthesis method of the present disclosure has high crystallinity, it is preferable to perform crystallization.

[0059] In particular, it is preferable to purify the compound represented by formula 3 by crystallization. That is, it is preferable to further include a crystallization step between step 2 and step 3. When purifying by crystallization, it is preferable that the reaction solvent is acetic acid-water. In this case, crystals of the compound represented by formula 3 are precipitated as the reaction proceeds. In this process, the target compound precipitates as crystals as the reaction proceeds, which prevents the generation of by-products due to decomposition caused by excessive reaction, and the purification effect is high. Therefore, in step 2, the by-production and inclusion of impurities can be suppressed without the need for complicated purification procedures using chromatography (see Figure 5(a)). On the other hand, when the compound represented by formula c is synthesized from the compound represented by formula b by the method described in Non-Patent Document 3, a large amount of impurities are by-produced (see FIG. 5(a)). Furthermore, since the compound represented by formula c is amorphous, a complicated purification procedure using chromatography is required for purification.

[0060] The crystals of the compound represented by formula 5 of the present disclosure can be stably stored for a long period of time, and can therefore be used as a bridged nucleoside intermediate. In addition, the crystals do not require a purification step by chromatography, and are therefore suitable for industrial production.

[0061] The crystal of the compound represented by formula 5 of the present disclosure can be synthesized by synthesizing a bridged nucleoside according to the publicly known description in Non-Patent Document 2 and the like, through the steps 6 to 10 shown below. Step 6: A step of suspending crystals of the compound represented by formula 5 in a solvent, and then converting the isopropylidene group of the compound to an acetyl group to obtain the compound represented by formula 6. Step 7: Condensing the compound of formula 6 with a silylated base to obtain the compound of formula 7 Step 8: A step of removing the protecting group of the compound represented by formula 7 and simultaneously carrying out a cyclization reaction to obtain a compound represented by formula 8. Step 9: Removing the hydroxyl-protecting group of the compound represented by formula 8 to obtain a compound represented by formula 9 Step 10: A step of introducing a protecting group into the amino group of the base moiety of the compound represented by formula 9, if necessary, to obtain a compound represented by formula 10.

[0062] [ka] In the above formula, R 1 is a protecting group for the hydroxyl group, R 2 is a leaving group, R 3 represents a hydrogen atom or an amino-protecting group.

[0063] In the above formula, the base may be thymine, uracil, adenine, cytosine, 5-methylcytosine, guanine, or other bases such as 2-thiouracil, 5-propynyluracil, 5-propynylcytosine, and 2,6-diaminopurine. Furthermore, during the process, these bases may be further converted into other bases by chemical reactions. The amino group on these bases may be protected with a protecting group such as an acyl group, such as an acetyl group, a phenoxyacetyl group, a benzoyl group, or an isobutyryl group, or a dimethylformamidino group.

[0064] Furthermore, those skilled in the art can easily understand from publicly known descriptions such as Non-Patent Document 2 that the above-mentioned bridged nucleosides can be converted into the corresponding bridged nucleoside amidites.

[0065] The method for producing a bridged nucleoside according to the present disclosure uses a stably stored crystal of the compound represented by formula 5 as a bridged nucleoside intermediate, and therefore can produce a variety of bridged nucleosides as needed.

[0066] Examples will be described below, but the present invention is not limited to the contents of the examples. EXAMPLES

[0067] Example 1 <Preparation of crystals of compound 5A> Starting from compound 1A, crystals of compound 5A were produced by the following process. In the formula, "BPMO" and "OMPB" both represent O groups to which a BPM group is bonded. In addition, "BPM" represents bromo(phenyl)methyl (also called 4-bromobenzyl).

[0068] [ka]

[0069] Compound 1A to Compound 2A (compounds represented by formula 2, R 1 = 4-bromobenzyl group) Compound 1A (20.43 g, 70.37 mmol) was dissolved in dimethylacetamide (dehydrated, 352 mL) and cooled to 0°C. Sodium hydride (60% by mass in oil, 7.04 g, 0.176 mol) was added, and the mixture was stirred for 1 hour. After that, 4-bromobenzyl bromide (44.0 g, 0.176 mol) was added, and the mixture was stirred at room temperature for 17 hours. Methanol (10 mL) was added to the reaction solution, and the mixture was stirred and concentrated. Ethyl acetate was added to the residue and washed with water. The organic layer was dried over anhydrous magnesium sulfate and concentrated to obtain compound 2A.

[0070] Compound 2A to Compound 3A (compounds represented by formula 3, R 1 = 4-bromobenzyl group) Compound 2A was dissolved in acetic acid (507 mL) by heating at 60°C, and 50 mL of an aqueous solution of sodium periodate (30.1 g, 0.141 mol) (253 mL, dissolved by heating at 60°C) was added. 5 minutes later, 30 mL was added, and the remaining portion was added over 5 minutes, and the mixture was stirred at the same temperature for 3 hours. The reaction solution was cooled to 0°C and stirred for 45 minutes, and the precipitated solid (crystals) was filtered. The mixture was washed with acetic acid:deionized water (volume ratio 2:1) and then with deionized water, and then dried in vacuum to obtain crystals of compound 3A (33.10 g, 59.51 mmol, 84.57%). 1 H-NMR(CDCl3,400MHz);δ9.89(1H,s),7.48-7.44(4H,m),7.20-7.09(4H,m),5.86(1H,d),4.66(1H,d),4.63(1 H,t),4.52(1H,s),4.47(1H,d),4.41(1H,d),4.31(1H,d),3.66(1H,d),3.60(1H,d),1.60(3H,s),1.36(3H,s).

[0071] Compound 3A to Compound 4A (compounds represented by formula 4, R 1 = 4-bromobenzyl group) Crystals of compound 3A (33.10 g, 59.51 mmol) were suspended in methanol (298 mL) and tetrahydrofuran (298 mL) and cooled to 0°C. Sodium borohydride (563 mg, 14.9 mmol) was added in small portions and stirred for 5 minutes, and the same amount of sodium borohydride (563 mg, 14.9 mmol) was added and stirred for 2 hours. The reaction solution was concentrated to a small volume, and then ethyl acetate was added to the residue and washed with a saturated aqueous solution of sodium bicarbonate. The organic layer was dried over anhydrous magnesium sulfate and concentrated to obtain compound 4A.

[0072] Compound 4A to Compound 5A (compounds represented by formula 5, R 1 = 4-bromobenzyl group, R 2 = 4-toluenesulfonyloxy group) crystals Compound 4A was azeotroped three times with pyridine, and the residue was dissolved in pyridine (dehydrated, 119 mL), and 4-toluenesulfonyl chloride (22.7 g, 0.119 mol) was added and stirred at 30°C for 17 hours. Deionized water (10 mL) was added and stirred, and the reaction solution was concentrated. Ethyl acetate was added to the residue and washed with saturated aqueous sodium bicarbonate. The organic layer was dried over anhydrous magnesium sulfate and concentrated, and the residue was azeotroped three times with toluene. The solidified residue was dissolved in ethyl acetate (50 mL), and hexane (100 mL) was added in small portions (crystal precipitation). Further hexane (100 mL) was added and left to stand overnight. The precipitated solid was collected by filtration, washed with hexane, and then vacuum dried to obtain crystals of compound 5A (32.22 g, 45.20 mmol, 75.95%). 1 H-NMR(CDCl3,400MHz);δ7.77(2H,d),7.45(2H,d),7.44(2H,d),7.29(2H,d),7.13(2H,d),7.08(2H,d),5.68(1H,d),4.63(1H,d),4.54(1 H,dd),4.44(1H,d),4.43(1H,d),4.38(1H,d),4.32(1H,d),4.14(1H,d),3.51(1H,d),3.48(1H,d),2.42(3H,s),1.29(3H,s),1.27(3H,s).

[0073] <Physical property measurement of crystals of compound 5A> The crystals of Compound 5A obtained above were measured for the following physical properties (1) to (4).

[0074] (1) Microscopic observation of crystal shape The crystal shape of the crystals of compound 5A was observed using a digital microscope, Dino-Lite AD-4113ZT (manufactured by AnMo Electronics Corporation), at a magnification of 230x.

[0075] (2) Powder X-ray analysis The crystals of compound 5A were subjected to powder X-ray analysis. The powder X-ray analyzer used was manufactured by Spectris Corporation, and the analysis conditions were as follows. [X-ray analysis equipment] X'Pert PRO MPD (Spectris Corporation) [Target] Cu [X-ray tube current] 40mA [X-ray tube voltage] 45kV [Scan range] 2θ=4.0~40°

[0076] The measurement results are shown in Figure 2. Compound 5A exhibited a characteristic peak near the diffraction angle (2θ) shown in FIG.

[0077] (3) Thermogravimetry / differential thermal analysis (TG / DTA) The crystals of compound 5A were subjected to thermogravimetry / differential thermal analysis (TG / DTA). The thermogravimetry / differential thermal analysis (TG / DTA) machine used was a thermal analyzer STA7200 (manufactured by Hitachi High-Tech Science Corporation), and the analysis conditions were as follows. Analysis conditions: The temperature was raised by 5°C per minute in the range of 30 to 190°C, and the change in the calorific value of the sample was measured. Aluminum oxide was used as a reference.

[0078] The measurement results are shown in Figure 3. The crystals of compound 5A showed an endothermic peak at 124°C.

[0079] (4) Accelerated stability testing The crystals of compound 5A were subjected to an accelerated stability test under the following conditions: 50 mg of the crystals of compound 5A was placed in a glass sample bottle and heated for 7 days at 80° C. 1 mg of the sample was dissolved in 1 mL of 5 mM triethylammonium acetate-70% by volume acetonitrile, and the purity was measured by high performance liquid chromatography. In addition, as a comparison, an acetonitrile solution of compound 5A was subjected to an accelerated test under the same conditions. 10 mg of crystals of compound 5A was dissolved in 1 mL of acetonitrile and heated at 80°C for 7 days. The sample solution was diluted 10 times with 5 mM triethylammonium acetate-70% by volume acetonitrile, and the purity was measured by high performance liquid chromatography. The results are shown in Figure 4.

[0080] When compound 5A was heated at 80° C. for 7 days, its purity decreased to 35% in the solution state, whereas almost no decomposition occurred in the crystalline state. This indicates that compound 5A can be stored stably for a long period of time without special care as long as it is stored in a crystalline state. On the other hand, it was found that compound 5A cannot be stored stably for a long period of time in a solution state, as in the existing synthesis method of bridged nucleoside intermediates.

[0081] <Comparison between step 2 of the present disclosure and the step described in non-patent document 3> The crystals of compound 3A obtained by the above method were compared with the solution properties of the compound represented by formula c synthesized under the conditions described in Non-Patent Document 3.

[0082] A process for obtaining a compound of formula c from a compound of formula b According to the method described in Non-Patent Document 3, a compound represented by formula c was produced from a compound represented by formula b.

[0083] The amount of impurities produced was confirmed by TLC under the following TLC conditions: TLC plate: Merck TLC Silica gel 60 F 254 Developing solvent: hexane:ethyl acetate = 2:1 (volume ratio)

[0084] The result of TLC for the crystals of compound 3A is shown in FIG. 5(a), and the result of TLC for the solution of the compound represented by formula c described in Non-Patent Document 3 is shown in FIG. 5(b). When compound 3A was synthesized by the above method, the target crystals precipitated as the reaction proceeded, and it was confirmed that highly pure compound 3A could be obtained simply by filtering the crystals without performing a chromatography operation. In contrast, in the reaction mixture of the compound represented by formula c synthesized under the conditions described in Non-Patent Document 3, the production of a by-product was observed in addition to the compound represented by formula c. Since the compound represented by formula c is amorphous, it became clear that a chromatography operation is required when further purification is performed to remove the by-product.

[0085] Example 2 Using the compound 5A produced in Example 1 as a starting material, various bridged nucleoside amidites of thymine, adenine, 5-methylcytosine, and guanine were produced.

[0086] (Example 2-1) Preparation of thymine-bridged nucleoside amidite The thymine-bridged nucleoside amidite 11T was synthesized from compound 5A.

[0087] [ka]

[0088] Compound 5A to Compound 6A (compounds represented by formula 6, R 1 = 4-bromobenzyl group, R 2 = 4-toluenesulfonyloxy group) Compound 5A (33.10 g, 59.51 mmol) was suspended in acetic acid (366 mL) and acetic anhydride (45.0 mL), and a solution (30.0 mL) of sulfuric acid (0.393 mL) in acetic acid was added, followed by stirring at room temperature for 2 hours. Sodium acetate (1.50 g) was added to the reaction solution, and after stirring, the solution was concentrated, and the residue was azeotroped with toluene five times. Ethyl acetate was added to the residue, and the residue was washed with a saturated aqueous solution of sodium bicarbonate. The organic layer was dried over anhydrous magnesium sulfate and concentrated to obtain compound 6A.

[0089] Compounds 6A to 7T (compounds represented by formula 7, R 1 = 4-bromobenzyl group, R 2 = 4-toluenesulfonyloxy group, Base = thymine) Compound 6A, thymine (7.96 g, 63.1 mmol), N,O-bis(trimethylsilyl)acetamide (33.9 mL, 0.139 mol) were added with acetonitrile (105 mL) and stirred at 85 ° C for 1 hour. After cooling the reaction solution to 0 ° C, trimethylsilyl trifluoromethanesulfonate (9.89 mL, 54.7 mmol) was added and stirred at 85 ° C for 4 hours. After cooling the reaction solution to 0 ° C, saturated aqueous sodium hydrogen carbonate solution was added and stirred. The precipitated solid was removed by filtration through Celite, and then extracted with ethyl acetate (the ethyl acetate layer can be washed with 1 M aqueous sodium hydroxide solution and then saturated aqueous ammonium chloride solution to remove the remaining thymine). The organic layer was dried over anhydrous magnesium sulfate and concentrated to obtain compound 7T.

[0090] Compounds 7T to 8T (compounds represented by formula 8, R 1 = 4-bromobenzyl group, Base = thymine) Methanol (211 mL) was added to compound 7T, sodium hydroxide (8.42 g, 0.211 mol) was added, and the mixture was stirred at 40° C. for 3 hours. A saturated aqueous solution of ammonium chloride was added to the reaction liquid, and the mixture was extracted with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate and concentrated, and then ethanol (150 mL) was added to the residue, and ethyl acetate was added until it dissolved. Ethyl acetate was distilled off under reduced pressure, and the precipitated solid was filtered and washed with ethanol. The obtained solid was dried in vacuum to obtain compound 8T (20.00 g, 32.88 mmol, 78.1%). 1 H-NMR(CDCl3,400MHz);δ8.39(1H,s),7.49(2H,d),7.46(2H,d),7.46(1H,d),7.18( 2H,d),7.14(2H,d),5.64(1H,s),4.62-4.45(5H,m),4.02-3.78(5H,m),1.70(3H,d).

[0091] A process for obtaining compound 9T (a compound represented by formula 9, Base=thymine) from compound 8T. Compound 8T (7.13 g, 11.7 mmol), ammonium formate (7.56 g, 0.12 mol) were dissolved in methanol (120 mL) and ethyl acetate (120 mL), and 20% by mass palladium hydroxide-activated carbon (20% by mass Pd, 50% by mass water content) (3.57 g) was added and stirred at 60° C. for 4 hours. After removing the catalyst by filtration through Celite, the filtrate was concentrated and purified by silica gel column chromatography (silica gel 150 mL, chloroform:methanol=10:1 (volume ratio)), to obtain compound 9T (3.22 g, 11.9 mmol, 102%). 1 H-NMR (D2O, 400MHz); δ7.66(1H,s),5.67(1H,s),4.49(1H,s),4.22(1H,s),4.05-4.03(3H,m),3.96(1H,d),1.91(3H,s).

[0092] A process for obtaining compound 10T from compound 9T Compound 9T (4.23 g, 15.7 mmol) was dissolved in pyridine (anhydrous, 52.3 mL), dimethoxytrityl chloride (7.45 g, 22.0 mmol) was added, and the mixture was stirred at room temperature for 4 hours. Methanol (5 mL) was added to the reaction solution, and the mixture was stirred and concentrated. Ethyl acetate was added to the residue, and the organic layer was washed with a saturated aqueous solution of sodium bicarbonate, and then the organic layer was dried over anhydrous magnesium sulfate and concentrated. The residue was azeotroped three times with toluene, and then purified by silica gel column chromatography (silica gel 250 mL, hexane:ethyl acetate = 1:1 to 1:2 (volume ratio) to ethyl acetate) to obtain compound 10T (8.99 g, 15.7 mmol, 100%). 1 H-NMR(CDCl3,400MHz);δ8.54(1H,s),7.65-6.84(14H,m),5.63(1H,s),4.43(1H,s),4.28(1H, d),3.88(2H,d),3.81(2H,d),3.80(6H,s),3.58(2H,d),3.47(2H,d),2.31(1H,d),1.70(3H,s).

[0093] A process for obtaining compound 11T from compound 10T Compound 10T (4.50 g, 7.86 mmol) and N,N-diisopropylethylamine (3.86 mL, 17.3 mmol) were dissolved in dichloromethane (dehydrated, 39.3 mL) and cooled to 0°C. 2-Cyanoethyldiisopropylchlorophosphoramidide (3.86 mL, 17.3 mmol) was added and stirred at room temperature for 1 hour. After washing the reaction solution with a saturated aqueous solution of sodium bicarbonate, the organic layer was dried over anhydrous magnesium sulfate and concentrated. The residue was purified by silica gel column chromatography (silica gel 200 mL, hexane:ethyl acetate = 1:1 (volume ratio)) to obtain compound 11T (6.00 g, 7.76 mmol, 98.7%). 31 P-NMR(CDCl3,160MHz);δ149.94,149.80.

[0094] (Example 2-2) Preparation of adenine-bridged nucleoside amidite

[0095] [ka]

[0096] Compound 5A to Compound 6A (compounds represented by formula 6, R 1 = 4-bromobenzyl group, R 2 = 4-toluenesulfonyloxy group) Compound 5A (24.0 g, 33.7 mmol) was suspended in acetic acid (340 mL, 0.1 mol / L), and acetic anhydride (35 mL, 262 mmol) and sulfuric acid (0.32 mL, 6.07 mmol) in acetic acid solution (371 mL) were added successively while stirring at room temperature, and the mixture was stirred at the same temperature for 3 hours. After the reaction was completed, sodium acetate (1.2 g, 14.5 mmol) was added at the same temperature, and the mixture was stirred at the same temperature for 5 minutes and then concentrated. The residue was azeotroped three times with toluene (340 mL). The obtained residue was dissolved in ethyl acetate (400 mL), and then washed three times with saturated sodium bicarbonate water (100 mL). The aqueous layer was extracted once with ethyl acetate (400 mL), and then all the obtained organic layers were combined, dried with magnesium sulfate, and the solvent was distilled off under reduced pressure, to obtain compound 6A.

[0097] Compounds 6A to 7A (compounds represented by formula 7, R 1 = 4-bromobenzyl group, R 2 = 4-toluenesulfonyloxy group, Base = N 6 -benzoyladenine) Compound 6A,N 6 -Benzoyladenine (12.1 g, 50.6 mmol) was added with toluene (85 mL, 0.4 mol / L), and then N,O-bis(trimethylsilyl)acetamide (25 mL, 101 mmol) was added while stirring at room temperature, and the mixture was stirred under heating and reflux for 1 hour. The temperature was then lowered to 0°C, and trimethylsilyl trifluoromethanesulfonate (7.9 mL, 43.8 mmol) was added at the same temperature, and the mixture was stirred under heating and reflux for 2 hours. After the reaction was completed, ethyl acetate (300 mL) and 1 mol / L aqueous sodium hydroxide solution (100 mL) were added at 0°C, and the mixture was stirred at the same temperature for 5 minutes. The precipitated solid was then removed by filtration, and the organic layer and the aqueous layer were separated. The obtained organic layer was washed three times with 1 mol / L aqueous sodium hydroxide solution (50 mL), and then dried with magnesium sulfate and the solvent was distilled off under reduced pressure, to obtain compound 7A.

[0098] Compounds 7A to 8A (compounds represented by formula 8, R 1 = 4-bromobenzyl group, Base = adenine) Methanol:tetrahydrofuran (9:1 (volume ratio), 170 mL) was added to compound 7A, and then sodium hydroxide (6.7 g, 169 mmol) was added and stirred at 40 ° C for 1 hour. After the reaction was completed, saturated ammonium chloride aqueous solution (170 mL) was added at the same temperature, and then stirred at the same temperature for 5 minutes. Subsequently, ethyl acetate (200 mL) was added, and after stirring, the precipitated solid was removed by filtration. After concentrating the filtrate, the residue was dissolved in ethyl acetate (400 mL), and the organic layer and the aqueous layer were separated. The obtained organic layer was washed once with deionized water (100 mL), and then dried with magnesium sulfate and the solvent was distilled off under reduced pressure. Methanol (67 mL, 0.5 mol / L) was added to the obtained residue, and the residue was completely dissolved by stirring under heating and reflux. Then, the temperature was lowered to room temperature, and the precipitated crystals were collected by stirring overnight. The obtained crystals were washed twice with methanol (20 mL) to obtain compound 8A (14.3 g, 23.2 mmol, 68.7%). 1 H-NMR(CDCl3, 400MHz); δ8.33(1H,s),7.99(1H,s), 7.47(2H,d),7.41(2H,d),7.18(2H,d),7.10(2H,d), 6.03(1H,s), 5.63(2H,brs), 4.87(1H,s),4.58(1H,d), 4.57(2H,dd), 4.48(1H,d), 4.26(1H,s), 4.11(1H,d),3.99(1H,d),3.81(2H,dd).

[0099] A step of obtaining compound 9A (a compound represented by formula 9, Base=adenine) from compound 8A. Compound 8A (14.3 g, 23.2 mmol) was added with ethyl acetate:methanol (1:3 (volume ratio), 600 mL), and then ammonium formate (21.9 g, 348 mmol) and deionized water (37 mL) were added and stirred at 60 ° C until dissolved. Palladium hydroxide-activated carbon (2.9 g) was then added at room temperature and stirred at 60 ° C for 17 hours. Subsequently, ammonium formate (7.3 g, 116 mmol) and palladium hydroxide-activated carbon (0.7 g) were added and stirred at 60 ° C for 24 hours. After the reaction was completed, the catalyst was removed by celite filtration, and the solvent was distilled off under reduced pressure to obtain compound 9A.

[0100] Compounds 9A to 10A (compounds represented by formula 10, Base (R 3 )=N 6 -benzoyladenine) Compound 9A was subjected to azeotropic dehydration (pyridine 100mL, 3 times), and pyridine (116mL, 0.2mol / L) was added thereto. Then, chlorotrimethylsilane (20.6mL, 162mmol) was added at 0°C, and the mixture was stirred at the same temperature for 30 minutes. Next, benzoyl chloride (13.5mL, 116mmol) was added at the same temperature, and the mixture was stirred for 21 hours. Then, methanol (116mL) was added, and the mixture was stirred at room temperature for 5 minutes, and then ammonia water (34mL) was added, and the mixture was stirred at the same temperature for 2.5 hours. After the reaction was completed, the precipitated solid was removed by filtration, and the solvent was distilled off under reduced pressure. Then, pyridine (100mL) was added, and the mixture was stirred for 5 minutes, and the undissolved solid was removed by filtration. The solvent was distilled off under reduced pressure to obtain compound 10A.

[0101] Step of obtaining compound 11A from compound 10A Pyridine (77mL, 0.3mol / L) was added to compound 10A, which had been subjected to azeotropic dehydration (pyridine 70mL, 3 times), and dimethoxytrityl chloride (9.6g, 28.2mmol) was added while stirring at room temperature, and the mixture was stirred at the same temperature for 1 hour. Subsequently, dimethoxytrityl chloride (11.8g, 34.8mmol) was added and stirred for 12 hours. After the reaction was completed, methanol (80mL) was added, and the mixture was stirred at the same temperature for 5 minutes, and the solvent was distilled off under reduced pressure. The resulting residue was dissolved in ethyl acetate (320mL), and then washed once with deionized water (80mL). After drying with magnesium sulfate and distilling off the solvent under reduced pressure, the mixture was purified by medium pressure silica gel column chromatography (SiO2100g, ethyl acetate:hexane=66:34 (volume ratio) to ethyl acetate) to obtain compound 11A (9.41g, 13.7mmol, 59.1%). 1 H-NMR(CDCl3, 400MHz); δ9.10(1H,s),8.77(1H,s),8.28(1H,s),8.02(2H,d),7.63-7.21(12H,m),6.85(4H ,d),6.13(1H,s),4.44(1H,d),4.04(2H,s),3.61(1H,d),3.56(1H,d),2.65(1H,d).

[0102] Obtaining compound 12A from compound 11A Compound 11A (9.41 g, 13.7 mmol) was subjected to azeotropic dehydration (toluene 70 mL, 3 times), and then dichloromethane (70 mL) and N,N-diisopropylethylamine (6.0 mL, 34.3 mmol) were added in sequence. Then, (2-cyanoethyl)(N,N-diisopropyl)chlorophosphoramidite (6.7 mL, 30.1 mmol) was added while stirring at 0 ° C., and the mixture was stirred at room temperature for 2.5 hours. After the reaction was completed, saturated sodium bicarbonate water (50 mL) was added at 0 ° C., and the mixture was stirred at the same temperature for 5 minutes, and the organic layer and the aqueous layer were separated. The aqueous layer was extracted once with ethyl acetate (70 mL), and all the organic layers obtained were combined, dried with magnesium sulfate, and the solvent was distilled off under reduced pressure in sequence. Thereafter, the mixture was purified by medium pressure silica gel column chromatography (SiO2 100 g, ethyl acetate:hexane=69:31 to 90:10 (volume ratio)) to obtain compound 12A (9.4 g, 10.6 mmol, 77.0%). 31 P-NMR(MeCN-d3,160MHz);δ149.54,149.04.

[0103] (Example 2-3) Preparation of 5-methylcytosine-bridged nucleoside amidite 5-Methylcytosine-bridged nucleoside amidite 12C was synthesized from compound 5A.

[0104] [ka]

[0105] Compound 5A to Compound 6A (compounds represented by formula 6, R 1 = 4-bromobenzyl group, R 2 = 4-toluenesulfonyloxy group) Compound 5A (30.0 g, 42.1 mmol) was suspended in acetic acid (366 mL) and acetic anhydride (45.0 mL), and a solution of concentrated sulfuric acid (396 μL) in acetic acid (30.0 mL) was slowly added dropwise, followed by stirring at room temperature for 2 hours. Sodium acetate (1.50 g, 18.3 mmol) was added to the reaction solution, and the mixture was stirred until completely dissolved, and then concentrated. The residue was azeotroped with toluene-ethyl acetate (volume ratio 2:1) (40 mL x 5), and ethyl acetate (300 mL) was added to the residue, which was then washed with a saturated aqueous solution of sodium bicarbonate (150 mL). The organic layer was dried over anhydrous magnesium sulfate and then concentrated. The residue was azeotroped with toluene (20 mL x 3) to obtain compound 6A.

[0106] Compounds 6A to 7C (compounds represented by formula 7, R 1 = 4-bromobenzyl group, R 2 = 4-toluenesulfonyloxy group, Base = N 4 -benzoyl-5-methylcytosine) Compound 6A was dissolved in acetonitrile (ultra-dehydrated) (105 mL) and 4 -benzoyl-5-methylcytosine (12.7 g, 55.4 mmol), N,O-bis(trimethylsilyl)acetamide (29.8 mL, 0.122 mol) were added, and the mixture was heated and stirred at 85° C. for 1 hour. After cooling the reaction mixture on ice, trimethylsilyl trifluoromethanesulfonate (11.4 mL, 63.1 mmol) was added, and the mixture was heated and stirred at 85° C. for 8 hours. After cooling the reaction mixture on ice, a saturated aqueous solution of sodium bicarbonate (150 mL) was added, and the mixture was stirred until the foaming ceased. The mixture was extracted with ethyl acetate (150 mL), and the organic layer was dried over anhydrous magnesium sulfate and concentrated to obtain compound 7C.

[0107] Compounds 7C to 8C (compounds represented by formula 8, R 1 = 4-bromobenzyl group, Base = 5-methylcytosine) Compound 7C was dissolved in tetrahydrofuran (21 mL), methanol (211 mL) and sodium hydroxide (8.42 g, 0.211 mol) were added, and the mixture was heated and stirred at 40° C. for 14 hours. The reaction solution was concentrated to a small volume, then diluted with ethyl acetate (200 mL), and washed with 1 mol / L hydrochloric acid (100 mL) and saturated aqueous sodium bicarbonate solution (100 mL). The organic layer was dried over anhydrous magnesium sulfate and then concentrated. The residue was dissolved in acetone (30 mL), and deionized water (15 mL) was added. Acetone was added until the solution became transparent, and the precipitated solid was filtered. The solid was washed with 50% ethanol by volume and then dried in vacuum to obtain compound 8C (18.71 g, 30.81 mmol, 73.17%). 1 H-NMR(CDCl3,400MHz);δ8.54(1H,s),7.50-7.42(5H,m),7,19-7.11(4H,m),5.71(1H,s),4.71(1 H,s),4.60-4.52(3H,m),4.38(1H,d),4.00(1H,d),3.87-3.79(4H,m),3.71(2H,s),1.67(3H,d).

[0108] A step of obtaining compound 9C (a compound represented by formula 9, Base=5-methylcytosine) from compound 8C Compound 8C (16.07 g, 26.46 mmol) was dissolved in tetrahydrofuran (142 mL) and methanol (142 mL), and ammonium formate (16.8 g, 0.266 mol) was added and dissolved. 1 mol / L hydrochloric acid (26.4 mL, 26.4 mmol) and palladium hydroxide-activated carbon (8.04 g) were added, and the mixture was heated and stirred at 60°C for 23 hours. Deionized water (27 mL) was added to dissolve the precipitate, and then the palladium hydroxide-activated carbon was removed by celite filtration and washed with 50% by volume methanol (100 mL x 5). The filtrate and washings were concentrated, and the residue was dissolved in deionized water (100 mL), and Dowex 50W x 8 (H + The target compound was adsorbed onto a column (60 mL) containing 0.2 to 0.5 mol / L ammonia water after washing the column with water. The fraction containing the target compound was concentrated and dried in vacuum to obtain compound 9C (6.83 g, 25.4 mmol, 96.0%). 1H-NMR (D2O, 400MHz); δ7.62(1H,s),5.66(1H,s),4.46(1H,s),4.19(1H,s),4.04(1H,d),4.04(2H,s),3.96(1H,d),1.98(3H,s).

[0109] Compounds 9C to 10C (compounds represented by formula 10, Base (R 3 )=N 4 -benzoyl-5-methylcytosine) Compound 9C (9.15 g, 34.0 mmol) was dissolved in pyridine (dehydrated) (118 mL), and benzoic anhydride (15.4 g, 68.1 mmol) was added and stirred at room temperature for 3 days. Ethanol (116 mL) and 2 mol / L aqueous sodium hydroxide solution (174 mL, 0.348 mol) were added to the reaction solution, and after stirring for 1 hour, acetic acid (23 mL) was added. After concentrating the reaction solution, the residue was azeotroped twice with deionized water. The residue was dissolved in deionized water (25 mL), and the precipitated solid was filtered and washed with water. The obtained solid was recrystallized from deionized water to obtain compound 10C (10.19 g, 27.29 mmol, 80.3%). 1 H-NMR (DMSO-d6,400MHz); δ8.15-7.45(6H,m),5.67(1H,d),5.46(1H,s),5.22(1H,t),4.17(1H,s),3.90(1H,d),3.83-3.63(4H,m),2.00(3H,s).

[0110] Step of obtaining compound 11C from compound 10C Compound 10C (7.00 g, 18.7 mmol) was azeotroped with pyridine three times, and then dissolved in pyridine (dehydrated) (62.3 mL). Dimethoxytrityl chloride (8.24 g, 24.3 mmol) was added, and the mixture was stirred at room temperature for 2 hours. Then, methanol (5 mL) was added to the reaction solution and concentrated. Ethyl acetate (200 mL) was added to the residue, and the mixture was washed with saturated aqueous sodium bicarbonate solution (50 mL). The organic layer was dried over anhydrous magnesium sulfate, concentrated, and the residue was azeotroped with toluene (20 mL x 3). The residue was purified by medium pressure silica gel column chromatography (SiO2 100 g, hexane:ethyl acetate = 2:1 to 1:1 to 1:3 (volume ratio)) under the following conditions to obtain compound 11C (12.14 g, 18.00 mmol, 96.26%). 1 H-NMR(CDCl3,400MHz);δ8.32(2H,d),7.83(1H,s),7.55-7.25(12H,m),6.89-6.85(4H,m),5.70(1H,s),4 .47(1H,s),4.29(1H,d),3.85(2H,dd),3.81(6H,s),3.62(1H,d),3.48(1H,d),1.90(3H,s),1.86(1H,d).

[0111] Obtaining compound 12C from compound 11C Compound 11C (11.50 g, 17.02 mmol) was dissolved in dichloromethane (ultra-dehydrated) (85.1 mL), N,N-diisopropylethylamine (6.02 mmol, 35.2 mmol), (2-cyanoethyl) (N,N-diisopropyl) chlorophosphoramidite (6.83 mL, 30.6 mmol) were added, and the mixture was stirred at room temperature for 2 hours. The reaction solution was diluted with chloroform (100 mL), and then washed with saturated aqueous sodium bicarbonate-saturated aqueous sodium chloride (50 mL + 50 mL). The organic layer was dried over anhydrous magnesium sulfate and then concentrated. The residue was purified by medium pressure silica gel column chromatography (SiO2 100 g, hexane:ethyl acetate = 3:1 to 2:1 to 1:1 (volume ratio)) under the following conditions to obtain compound 12C (10.70 g, 12.22 mmol, 71.80%). 31 P-NMR(CDCl3,160MHz);δ150.10,150.04.

[0112] (Example 2-4) Preparation of guanine-bridged nucleoside amidite Guanine-bridged nucleoside amidite 13G was synthesized from compound 5A.

[0113] [ka]

[0114] Compound 5A to Compound 6A (compounds represented by formula 6, R 1 = 4-bromobenzyl group, R 2 = 4-toluenesulfonyloxy group) Compound 5A (30.0 g, 42.1 mmol) was suspended in acetic acid (366 mL) and acetic anhydride (45.0 mL), and a solution of concentrated sulfuric acid (396 μL) in acetic acid (30.0 mL) was slowly added dropwise, followed by stirring at room temperature for 2 hours. Sodium acetate (1.50 g, 18.3 mmol) was added to the reaction solution, and the mixture was stirred until completely dissolved, and then concentrated. The residue was azeotroped with toluene-ethyl acetate (volume ratio 2:1) (40 mL x 5), and ethyl acetate (300 mL) was added to the residue, which was then washed with a saturated aqueous solution of sodium bicarbonate (150 mL). The organic layer was dried over anhydrous magnesium sulfate and then concentrated. The residue was azeotroped with toluene (20 mL x 3) to obtain compound 6A.

[0115] Compounds 6A to 7G (compounds represented by formula 7, R 1 = 4-bromobenzyl group, R 2 = 4-toluenesulfonyloxy group, Base = 2-amino-chloropurine) Compound 6A was dissolved in acetonitrile (ultra-dehydrated) (105 mL), 2-amino-6-chloropurine (10.7 g, 63.1 mmol), N,O-bis(trimethylsilyl)acetamide (33.9 mL, 0.137 mol) were added, and the mixture was heated and stirred at 85 ° C for 1 hour. After cooling the reaction solution on ice, trimethylsilyl trifluoromethanesulfonate (15.2 mL, 84.1 mmol) was added, and the mixture was heated and stirred at 85 ° C for 7 hours. After cooling the reaction solution on ice, a saturated aqueous solution of sodium bicarbonate was added, and the mixture was stirred until the foaming ceased. The mixture was extracted with ethyl acetate (150 mL), and the organic layer was washed with a 1 M aqueous solution of sodium hydroxide, dried over anhydrous magnesium sulfate, and concentrated to obtain compound 7G.

[0116] Compounds 7G to 8G (compounds represented by formula 8, R 1 = 4-bromobenzyl group, Base = 2-amino-6-methoxypurine) Compound 7G was dissolved in tetrahydrofuran (105 mL), methanol (421 mL) and 25% by volume sodium methoxide methanol solution (80.9 mL) were added, and the mixture was heated and stirred at room temperature for 24 hours. The reaction solution was neutralized with 2M hydrochloric acid and then concentrated. Ethyl acetate was added to the residue, and the mixture was washed with a saturated aqueous solution of sodium bicarbonate. The organic layer was dried over anhydrous magnesium sulfate and then concentrated. The residue was dissolved in ethyl acetate, activated carbon (1.0 g) was added, and the mixture was heated and stirred at 60°C for 1 hour. The activated carbon was removed by filtration through Celite, and the filtrate was concentrated to obtain compound 8G.

[0117] A step of obtaining compound 9G (a compound represented by formula 9, Base=2-amino-6-methoxypurine) from compound 8G Compound 8G was dissolved in tetrahydrofuran (213 mL) and methanol (213 mL), and ammonium formate (26.9 g, 0.427 mol) was added and dissolved. Palladium hydroxide-activated carbon (13.5 g) was added, and the mixture was heated and stirred at 60°C for 30 hours. The palladium hydroxide-activated carbon was removed by filtration through Celite, and washed with methanol (100 mL x 5). The filtrate and washings were concentrated, and the residue was dissolved in deionized water (300 mL) and washed with toluene. The solution was diluted with IRA93(OH) - The extract was passed through a column (150 mL) of 2-hexanediaminetetraacetate, washed with water, and then concentrated to give compound 9G.

[0118] A step of obtaining compound 10G (a compound represented by formula 9, Base=guanine) from compound 9G. Compound 9G was dissolved in 100 mM Tris-HCl (pH 7.5) (420 mL), adenosine deaminase (37 μL, 42 units) was added, and the mixture was stirred at 40° C. for 24 hours. Adenosine deaminase (37 μL, 42 units) was added, and the mixture was stirred at the same temperature for another 24 hours. The precipitated solid was collected by filtration, washed with water, and then dried in vacuum to obtain compound 10G (8.50 g, 28.8 mmol, 68.4%). 1 H-NMR(DMSO-d6,400MHz);δ10.63(1H,s),7.79(1H,s),6.56(2H,s),5.68-5.67(2H ,m),5.03(1H,t),4.28(1H,s),4.14(1H,d),3.88(1H,d),3.77(2H,m),3.71(1H,d).

[0119] Compounds 10G to 11G (compounds represented by formula (10), Base (R 3 )=N 2 -isobutyrylguanine) Compound 10G (600 mg, 2.03 mmol) was dissolved in N,N-dimethylformamide (dehydrated) (4.1 mL), tert-butylchlorodimethylsilane (1.22 g, 8.09 mmol) was added, and the mixture was stirred at room temperature for 20 hours. The reaction solution was diluted with ethyl acetate and washed with water, and the organic layer was dried over anhydrous magnesium sulfate and concentrated. The residue was purified by silica gel column chromatography (SiO2 100 mL, chloroform:methanol = 20:1 (volume ratio)). The residue was dissolved in pyridine (8.0 mL), and ice-cooled isobutyryl chloride (336 μL, 3.18 mmol) was added, followed by stirring at room temperature for 20 hours. Deionized water was added and the mixture was stirred, after which the reaction solution was concentrated. Ethyl acetate was added to the residue, and the mixture was washed with saturated sodium bicarbonate water, after which the organic layer was dried over anhydrous magnesium sulfate and concentrated. The residue was azeotroped three times with toluene, and then the residue was purified by silica gel column chromatography (SiO2 100 mL, chloroform:methanol = 50:1 (volume ratio)). The residue was dissolved in methanol (10.0 mL), and acidic ammonium hydrogen fluoride (860 mg, 15.0 mmol) was added, followed by heating and stirring for 17 hours at 60° C. Silica gel was added to the reaction solution, the solvent was distilled off, and the mixture was purified by silica gel column chromatography (SiO2 100 mL, chloroform:methanol = 10:1 to 5:1 (volume ratio)) to obtain compound 11G (0.53 g, 1.5 mmol, 74%). 1 H-NMR(DMSO-d6,400MHz);δ12.11(1H,s),11.77(1H,s),8.09(1H,s),5.80(1H,s),5.73(1 H,d),5.06(1H,t),4.37(1H,s),4.15(1H,d),3.92-3.72(4H,m),2.77(1H,m),1.12(6H,d).

[0120] Obtaining compound 12G from compound 11G Compound 11G (1.87 g, 5.12 mmol) was azeotroped with pyridine three times, and then dissolved in pyridine (dehydrated) (17.1 mL). Dimethoxytrityl chloride (2.43 g, 7.17 mmol) was added, and the mixture was stirred at room temperature for 2 hours. Then, methanol (1 mL) was added to the reaction solution and concentrated. Ethyl acetate (200 mL) was added to the residue, and the mixture was washed with a saturated aqueous solution of sodium bicarbonate. The organic layer was dried over anhydrous magnesium sulfate, concentrated, and the residue was azeotroped with toluene (20 mL x 3). The residue was purified by silica gel column chromatography (SiO2 150 g, hexane:ethyl acetate = 1:1 to 1:3 (volume ratio) to ethyl acetate) to obtain compound 12G (3.27 g, 4.90 mmol, 95.7%). 1 H-NMR(DMSO-d6,400MHz);δ12.05(1H,s),8.93(1H,s),7.88(1H,s),7.44-7.13(9H,m),6.79(4H,m),5.78(1H,s),4.60(1H,s),4. 44(1H,s),4.05(1H,d),3.99(1H,d),3.74(3H,s),3.74(3H,s),3.61(1H,d),3.55(1H,d),2.64(1H,m),1.24(3H,d),1.23(3H,d).

[0121] Obtaining compound 13G from compound 12G Compound 12G (3.20 g, 4.79 mmol) was dissolved in dichloromethane (ultra-dehydrated) (24.0 mL), N,N-diisopropylethylamine (2.03 mL, 11.9 mmol), (2-cyanoethyl) (N,N-diisopropyl) chlorophosphoramidite (2.35 mL, 10.5 mmol) were added, and the mixture was stirred at room temperature for 3 hours. The reaction solution was washed with a saturated aqueous solution of sodium bicarbonate. The organic layer was dried over anhydrous magnesium sulfate and then concentrated. The residue was purified by silica gel column chromatography (SiO2 200 g, hexane: ethyl acetate = 1: 1 to 1: 2 (volume ratio)) to obtain compound 13G (3.36 g, 3.87 mmol, 80.8%). 31 P-NMR(MeCN-d3,160MHz);δ149.09,148.74.

Claims

[Claim 1] A crystal of the compound represented by formula 5. 【Chemistry 1】 In the above formula, R 1 is a protecting group for a hydroxyl group, R 2 indicates a leaving group.

Citation Information

Patent Citations

  • New bicyclo nucleotide and oligonucleotide analogue

    JP1998304889A

  • Oligonucleotide analog

    JP2002521310A